Xoma presents botulinum toxin antibody

XOMA Ltd., a therapeutic antibody manufacturer, has recently given multiple presentations about advances in their biodefense program, including the three antibody formulation XOMA 3AB that binds to specific regions of botulinum toxin type A.  

This presentation included information about the successful lyophilization of XOMA 3AB and a demonstration of the formulation stored at various temperature ranges. The presentation occurred as part of the 5th Annual Public Health Emergency Medical Countermeasures Enterprise Stakeholders Workshop and BARDA Industry Day held from January 10 through January 12 in Washington, D.C.

In preclinical studies, XOMA 3AB has been shown to neutralize botulin

um type A, which is considered an extremely deadly bioterrorism threat. The antibody formulation is being developed using funding by the National Institute of Allergy and Infectious Diseases, which is a division of the National Institutes of Health. XOMA has entered into U.S. government contracts for this projects worth over $100 million.

"The PHEMCE meeting is a leading venue for providing scientists and government leaders with up-to-date information on the excellent progress in our anti-botulinum toxin program," Steve B. Engle, XOMA's chairman and chief executive officer, said. "Our presentations at this conference clearly emphasize our expertise and technical leadership position in this strategically important space."

XOMA is also currently developing an antibody for diabetes and inflammatory conditions along with multiple other conditions related to autoimmune, cardio-metabolic, ophthalmic, oncologic and inflammatory diseases. 

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.